JP2024506321A - 呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法 - Google Patents

呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法 Download PDF

Info

Publication number
JP2024506321A
JP2024506321A JP2023547808A JP2023547808A JP2024506321A JP 2024506321 A JP2024506321 A JP 2024506321A JP 2023547808 A JP2023547808 A JP 2023547808A JP 2023547808 A JP2023547808 A JP 2023547808A JP 2024506321 A JP2024506321 A JP 2024506321A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
antibodies
seq
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506321A5 (https=
Inventor
コルティ，ダヴィデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2024506321A publication Critical patent/JP2024506321A/ja
Publication of JP2024506321A5 publication Critical patent/JP2024506321A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023547808A 2021-02-09 2022-02-08 呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法 Pending JP2024506321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147676P 2021-02-09 2021-02-09
US63/147,676 2021-02-09
PCT/US2022/015652 WO2022173745A1 (en) 2021-02-09 2022-02-08 Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same

Publications (2)

Publication Number Publication Date
JP2024506321A true JP2024506321A (ja) 2024-02-13
JP2024506321A5 JP2024506321A5 (https=) 2025-02-19

Family

ID=80461207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547808A Pending JP2024506321A (ja) 2021-02-09 2022-02-08 呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法

Country Status (8)

Country Link
US (1) US20240101648A1 (https=)
EP (1) EP4291575A1 (https=)
JP (1) JP2024506321A (https=)
CN (1) CN117136197A (https=)
BR (1) BR112023015900A2 (https=)
CA (1) CA3210502A1 (https=)
TW (1) TW202246317A (https=)
WO (1) WO2022173745A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2015514068A (ja) * 2012-03-20 2015-05-18 フマブス バイオメッド エスアー Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2019503648A (ja) * 2015-10-29 2019-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト呼吸器合胞体ウイルスを中和する抗体
WO2019125846A1 (en) * 2017-12-19 2019-06-27 The Rockefeller University HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
JP2019534003A (ja) * 2016-10-21 2019-11-28 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2019024979A1 (en) * 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2015514068A (ja) * 2012-03-20 2015-05-18 フマブス バイオメッド エスアー Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2019503648A (ja) * 2015-10-29 2019-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト呼吸器合胞体ウイルスを中和する抗体
JP2019534003A (ja) * 2016-10-21 2019-11-28 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
WO2019125846A1 (en) * 2017-12-19 2019-06-27 The Rockefeller University HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAT. MICROBIOL., vol. 2, no. 16272, JPN5024009044, 2017, pages 1 - 14, ISSN: 0005775297 *
NATURE, vol. 501, no. 7467, JPN5024009043, 2013, pages 439 - 443, ISSN: 0005775296 *

Also Published As

Publication number Publication date
CN117136197A (zh) 2023-11-28
TW202246317A (zh) 2022-12-01
WO2022173745A1 (en) 2022-08-18
US20240101648A1 (en) 2024-03-28
BR112023015900A2 (pt) 2023-10-17
CA3210502A1 (en) 2022-08-18
EP4291575A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
TW202146442A (zh) 抗sars-cov-2抗體及使用其之方法
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
US20240092876A1 (en) Broadly neutralizing antibodies against influenza neuraminidase
US20240141021A1 (en) Anti-influenza antibodies and combinations thereof
CA3194162A1 (en) Antibodies against sars-cov-2
JP2023550785A (ja) 複数のベータコロナウイルスに結合する抗体
TWI901812B (zh) 針對a型流感病毒的抗體
JP2024506321A (ja) 呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
TW202411247A (zh) 針對流感神經胺酸酶的廣泛中和抗體
WO2023230448A1 (en) Combination immunotherapy for influenza
CN116997567A (zh) 抗流感抗体和其组合
WO2024118998A2 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same
CN116888157A (zh) 针对流感神经氨酸苷酶的广泛中和抗体
WO2024112818A1 (en) Engineered anti-sars-cov-2 antibodies and uses thereof
EA051192B1 (ru) Антитела против вирусов гриппа а
CN116981687A (zh) 针对甲型流感病毒的抗体

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417